Related Experiment Videos
[TNF-alpha inhibitors in inflammatory bowel disease]
1Servei de Digestiu, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Medicina Clinica
|November 18, 2004
Summary
Tumor necrosis factor alpha (TNFalpha) antagonists, like infliximab, are effective biological therapies for Crohn's disease, but not ulcerative colitis. Research continues to improve these treatments and reduce side effects.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Context:
- Inflammatory bowel disease (IBD) involves chronic intestinal inflammation driven by mediators like tumor necrosis factor alpha (TNFalpha).
- Biological therapies targeting TNFalpha have emerged as a significant advancement in IBD management.
- Infliximab is a key anti-TNFalpha monoclonal antibody approved for IBD treatment.
Purpose:
- To review the role of TNFalpha antagonism in IBD treatment.
- To evaluate the efficacy and drawbacks of infliximab in Crohn's disease and ulcerative colitis.
- To discuss the future of biological therapies in IBD.
Summary:
- Infliximab effectively treats Crohn's disease, inducing remission and healing fistulas, but is not effective for ulcerative colitis.
- Adverse effects of infliximab include antibody development, loss of efficacy, hypersensitivity, autoimmunity, and infection reactivation (e.g., tuberculosis).
- Ongoing research focuses on humanized or fully human anti-TNFalpha agents to mitigate infliximab's immunogenicity and side effects.
Impact:
- Anti-TNFalpha therapies, particularly infliximab, represent a major therapeutic advance for Crohn's disease.
- Understanding TNFalpha's role has paved the way for targeted biological treatments in IBD.
- Future developments in selective TNFalpha antagonism hold promise for improved IBD management.